However, Wegovy has a distinct advantage for patients with cardiovascular risks, as it is FDA-approved to reduce major adverse cardiovascular events (MACE) by 20%, a benefit Mounjaro does not currently provide
The Lancet, 337(8750), 1121-1124
Another hindering factor is costthese medications are relatively expensive , and many patients have trouble affording them
For type 2 diabetes mellitus, options include semaglutide (Ozempic), dulaglutide (Trulicity), liraglutide (Victoza), and exenatide (Byetta, Bydureon)
Platforms that publish no clinician identity or credentials carry meaningfully higher risk than those that name their providers
As a result, GLP-1 coverage for medically accepted FDA-approved indications other than obesity is required while access to GLP-1s to treat obesity under Medicaid is currently limited